

ATLANTA, Sept. 21, 2013 /PRNewswire/ – Elekta today announced Monaco® 5.0, which consolidates support for all of the most clinically useful delivery techniques in a single treatment planning system, and features refinements to planning speed and precision.

"This latest Monaco release brings together the best capabilities of Elekta's treatment planning portfolio into a single planning system to achieve a greater level of convenience and clinical versatility for the radiation oncology team," says **Todd Powell**, Executive Vice President of Elekta Software. "And, with a new system architecture, sophisticated treatment plans can now be developed with speeds often not attainable with previous planning systems."

Uniquely relying on an advanced Monte Carlo dose engine – considered the gold standard for calculating delivered radiation – **Monaco** is now a truly comprehensive treatment planning system, supporting the full breadth of radiation therapy techniques, including VMAT, IMRT, and 3D conformal radiation therapy. The system is exceptionally equipped for advanced stereotactic therapies, such as SRS and SRT, with added planning support for specialized beam shaping devices, including circular cones.

"Developing treatment plans can be a resource-intensive task that limits a clinic's productivity and throughput," says **Richard Stark**, Senior Vice President of Elekta Software. "With a reinvented workflow and user interface, **Monaco 5.0** is designed to simplify and accelerate the radiotherapy planning process. Combining these capabilities with a new system architecture based on CPU [central processor unit] and GPU-based [graphics processor unit] technology, **Monaco** sets a new standard in accuracy and speed."

# Elekta Announces Monaco 5.0 -- Comprehensive Radiation Treatment Planning Capabilities Brought Together

Written by Australian Business

---

Learn more at [www.elekta.com/Monaco](http://www.elekta.com/Monaco) .

*3D conformal radiation therapy, stereotactic cone and GPU-based architecture are pending FDA 510(k) clearance.*

**For further information, please contact:**Johan Andersson, Director, Investor Relations, Elekta AB

Tel: +46 702 100 451, email:

[johan.andersson@elekta.com](mailto:johan.andersson@elekta.com)

Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta Tel: +1

770-670-2447, email:

[michelle.joiner@elekta.com](mailto:michelle.joiner@elekta.com)

Time zone: ET: Eastern Time

**About Elekta** Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTA. Website: [www.elekta.com](http://www.elekta.com) .

SOURCE Elekta

RELATED LINKS <http://www.elekta.com>